Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4- (phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor

Journal of Medicinal Chemistry

Volumn 42, Issue 10, 1999, Pages 1803-1815

  Smaill, Jeff B ^a   Palmer, Brian D ^a   Rewcastle, Gordon W ^a   Denny, William A ^a   McNamara, Dennis J ^b   Dobrusin, Ellen M ^b   Bridges, Alexander J ^b   Zhou, Hairong ^b   Showalter, H D Hollis ^b   Winters, R Thomas ^b   Leopold, Wilbur R ^b   Fry, David W ^b   Nelson, James M ^b   Slintak, Veronika ^b   Elliot, William L ^b   Roberts, Billy J ^b   Vincent, Patrick W ^b   Patmore, Sandra J ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (PHENYLAMINO)PYRIDO[D]PYRIMIDINE ACRYLAMIDE; 4 (PHENYLAMINO)QUINAZOLINE; CYSTEINE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; CANCER INHIBITION; EMULSION; ENZYME ACTIVITY; ENZYME ASSAY; LUNG NON SMALL CELL CANCER; PARTICULATE MATTER; SIGNAL TRANSDUCTION; TITRIMETRY; XENOGRAFT;

ACRYLAMIDES; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033587022     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9806603     Document Type: Article

References (45)

1. Hickey, K.; Grehan, D.; Reid, I. M.; O'Briain, S.; Walsh, T. N.; Henneasy, T. P. J. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994, 74, 1693-1698.
2. Delarue, J. C.; Terrier, P.; Terrier-Lacombe, M. J.; Mouriesse, H.; Gotteland, M.; May-Levin, F. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGFR) could be predictive of early and long-term outcome in human breast cancer: a pilot study. Bull. Cancer 1994, 81, 1067-1077.
3. Bridges, A. J. The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target? Curr. Med. Chem. 1998, 3, 167-194.
4. Fry, D. W. Recent advances in tyrosine kinase inhibitors. Annu. Rep. Med. Chem. 1998, 31, 151-160.
5. (a) Traxler, P. M. Protein tyrosine kinase inhibitors in cancer treatment (Part I). Exp. Opin. Ther. Pat. 1997, 7, 571-588;
6. (b) Exp. Opin. Ther. Pat. 1998, 8, 1599-1625.
7. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
8. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
9. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
10. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge, S. A.; Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 1996, 38, 67-73.
11. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3780-3788.
12. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
13. Fry D. W.; Nelson, J. M.; Slintak, V.; Keller, P. R.; Rewcastle, G. W.; Denny, W. A.; Zhou, H.; Bridges, A. J. Biochemical and antiproliferative properties of 4-[Ar(alkyl)amino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol. 1887, 54, 877-887.
14. Iwata, K.; Miller, P. E.; Barbacci, E. G.; Arnold, L.; Doty, J.; DiOrio, C. I.; Pustilnik, L. R.; Reynolds, M.; Thelemann, A.; Sloan, D.; Moyer, J. D. CP-358,774: a selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. Proc. Am. Assoc. Cancer Res. 1997, 38, 633 (Abstract 4248).
15. Woodburn, J. R.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B. J.; Scarlett, L.; Henthom, L. R. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Cancer Res. 1997, 38, 633 (Abstract 4251).
16. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Gries, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12022-12027.
17. Wissner, A.; Johnson, B. D.; Floyd, M. B.; Kitchen, D. B. 4-Aminoquinazolines as EGFR inhibitors. U.S. Patent 5,760, 041, June 2, 1998.
18. Singh, J.; Dobrusin, E. M.; Fry, D. W.; Haske, T.; Whitty, A.; McNamara, D. J. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 1997, 40, 1130-1135.
19. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
20. Thompson, A. M.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Nelson, J. A.; Showalter, H. D. H.; Roberts, B. J.; Vincent, P. W.; Denny, W. A. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 3915-3925.
21. Rewcastle, G. W.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Howard, C. T.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Showalter, H. D. H.; Winters, R. T.; Denny, W. A. Tyrosine Kinase Inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 1998, 41, 742-751.
22. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
23. Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Rubin, R. W.; Denny, W. A. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido-[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 1820-1826.
24. Fry, D. W.; Nelson, J. M.; Slintak, V.; Keller, P. R.; Rewcastle, G. W.; Denny, W. A.; Zhou, Z.; Bridges, A. J. Biochemical and antiproliferative properties of 4-[Ar(alkyl)amino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol. 1997, 54, 877-887.
25. Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Rihs, G.; Lydon, N.; Traxler, P. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1994, 37, 1015-1027.
26. Hudson, A. T.; Vile, S.; Barraclough, P.; Franzmann, K. W.; McKeown, S. C.; Page, M. J. Substituted heteroaromatic compounds and their use in medicine. PCT Int. Appl. WO96/09294, 1996; Chem. Abstr. 1996, 725, 114665a.
27. Hudson, A. T.; Vile, S.; Barraclough, P.; Franzmann, K. W.; McKeown, S. C.; Page, M. J. Substituted heteroaromatic compounds and their use in medicine. PCT Int. Appl. WO96/09294, 1996; Chem. Abstr. 1996, 725, 114665a.
28. Nelson, J. M.; Slintak, V.; Denny, W. A.; Smaill, J. B.; Rewcastle, G. W.; Showalter, H. D. H.; Bridges, A. J.; Zhou, H.; McNamara, D. J.; Dobrusin, E. M.; Fry, D. W. In vitro comparison of irreversible versus reversible inhibition for a series of substituted quinazolines and pyridopyrimidines that are potent and specific inhibitors of the epidermal growth factor receptor (EGFR) family of tyrosine kinases. Proc. Am. Assoc. Cancer Res. 1998, 39, 316 (Abstract 2158).
29. Vincent, P. W.; Atkinson, B. E.; Zhou, H.; Dykes, D.; Leopold, W. R.; Patmore, S. J.; Roberts, B. J.; Bridges, A. J.; Elliott, W. L. Characterization of the in vivo activity of a novel EGF receptor family kinase inhibitor, PD 169414. Proc. Am. Assoc. Cancer Res. 1998, 39, 560 (Abstract 3807).
30. Derbyshire, D. H.; Waters, W. A. The significance of the bromine cation in aromatic substitution. Part II. Preparative applicability. J. Chem. Soc. 1950, 573-577.
31. Bunnett, J. F.; Rauhut, M. M. The von Richter reaction. III. Substituent effects. J. Org. Chem. 1956, 21, 934-938.
32. Quang, N. N.; Diep, B. K.; Buu-Hoi, N. P. Orientation during the Friedel-Crafts acetylation of bromofluorobenzenes. Recl. Trav. Chim. Pay-Bas 1964, 83, 1142-1148.
33. Morley, J. S.; Simpson, J. C. E. The chemistry of simple heterocyclic systems. Part 1. Reactions of 6- and 7-nitro-4-hydroxyquinazoline and their derivatives. J. Chem. Soc. 1948, 360-366.
34. Barker, A. J. Quinazoline derivatives. Eur. Pat. Appl. 566 226 A1, 1993; Chem. Abstr. 1994, 120, 217715t.
35. Barker, A. J. Quinazoline derivatives. Eur. Pat. Appl. 566 226 A1, 1993; Chem. Abstr. 1994, 120, 217715t.
36. Barker, A. J. Preparation of haloanilinoquinazolines as Class I receptor tyrosine kinase inhibitors. PCT Int. Appl. WO96 33 979, 1996; Chem. Abstr. 1997, 126, 31371w.
37. Barker, A. J. Preparation of haloanilinoquinazolines as Class I receptor tyrosine kinase inhibitors. PCT Int. Appl. WO96 33 979, 1996; Chem. Abstr. 1997, 126, 31371w.
38. Himmelsbach, F.; Dahmann, G.; Von Ruden, T.; Metz, T. Preparation of 4-aminopyrimidine derivatives as antitumor agents. PCT Int. Appl. WO97 32 881, 1997; Chem. Abstr. 1997, 127, 278207v.
39. Himmelsbach, F.; Dahmann, G.; Von Ruden, T.; Metz, T. Preparation of 4-aminopyrimidine derivatives as antitumor agents. PCT Int. Appl. WO97 32 881, 1997; Chem. Abstr. 1997, 127, 278207v.
40. Miyake, Y.; Kikugawa, Y. Synthesis of 6-methoxyindoles and indolines. Regioselective C-6 bromination of indolines and subsequent nucleophilic substitution with a methoxyl group. J. Hetencycl. Chem. 1983, 20, 349-352.
41. Fry, D. W.; Kraker, A. J.; Connors, R. C.; Elliott, W. L.; Nelson, J. M.; Showalter, H. D. H.; Leopold, W. R. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Des. 1994, 9, 331-351.
42. Schabel, F. M., Jr.; Griswold, D. P., Jr.; Laster, W. R., Jr.; Corbett, T. H.; Lloyd, H. H. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol. Ther. 1977, 1, 411-435.
43. Leopold, W. R.; Nelson, J. M.; Plowman, J.; Jackson, R. C. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res. 1985, 45, 5532-5539.
44. Elliott, W. L.; Howard, C. T.; Dykes, D. J.; Leopold, W. R. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res. 1989, 49, 5586-5590.
45. Elliott, W. L.; Roberts, B. J.; Howard, C. T.; Leopold, W. R. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato-(2-)](2-methyl-1,4-butanediamine-N, N′) platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Cancer Res. 1994, 54, 4412-4418.